CL
STLNW

CSS LLC’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

CSS LLC’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,136
Closed -$10K – 1319
2021
Q4 		$10K Buy
+14,136
New +$17.5K ﹤0.01% 1207

Other funds holding STLNW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CSS LLC's STLNW Position: Q1 2022 in Review

CSS LLC sold out of Starling Oncology, Inc. Warrant (STLNW) in Q1 2022, closing a stake of 14,136 shares — an estimated $10K sold.

CSS LLC first reported a position in STLNW in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

  • CSS LLC reported no remaining Starling Oncology, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
  • CSS LLC sold 14,136 Starling Oncology, Inc. Warrant shares in Q1 2022, an estimated $10K.
  • CSS LLC first reported a position in Starling Oncology, Inc. Warrant in Q4 2021 and held it in 1 quarter.
  • CSS LLC's Starling Oncology, Inc. Warrant position peaked at $10K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q1 2022.

Based on CSS LLC's 13F filing for Q1 2022, filed 16 May 2022.